Upload
Featured Recent Articles Topics Upload Login Sign Up

Search Results for 'fda data'

fda data published presentations and documents on DocSlides.

FDA’s New Final Guidance on
FDA’s New Final Guidance on
by pasty-toler
Drug Inspections. Anne K. Walsh. FDLI Enforcement...
FDA Perspective on the development and use of
FDA Perspective on the development and use of
by osullivan
Epidemiological cut-off values (ECVs). Simone M. S...
FDA Regulation of Menthol in Tobacco Products
FDA Regulation of Menthol in Tobacco Products
by pamella-moone
Patricia Kovacevic.   Director, Regulatory . Aff...
Post-FDA Approval, Initial US Clinical Experience with Watc
Post-FDA Approval, Initial US Clinical Experience with Watc
by phoebe-click
Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2....
THE FDA WEBSITE
THE FDA WEBSITE
by min-jolicoeur
IMPROVING. TRANSPARENCY. AND EFFECTIVENESS. Steph...
Sponsor-Investigator (SI) FDA Inspections
Sponsor-Investigator (SI) FDA Inspections
by eurolsin
Christiana Provencal, M.A.. Quality Assurance / Qu...
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
by carny
Jeff Shuren, MD, JD. Center for Devices and Radiol...
FDA's role in the innovation and
FDA's role in the innovation and
by josephine
evaluation of evolving . computer-aided diagnosis ...
SHEDDING LIGHT ON AN FDA VISIT
SHEDDING LIGHT ON AN FDA VISIT
by CuteAsACupcake
Joyce Nancarrow Tull, MSN, RN, CCRP. University of...
FDA Pre-Submission Meetings
FDA Pre-Submission Meetings
by violet
for 510(k) Submissions. Consultants and RA Experts...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Clinical Trial Data Integrity:
Clinical Trial Data Integrity:
by phoebe-click
Bi. oresearch . Mo. nitoring Program. Jur Strobos...
It is the policy of the University of Arkansas for Med
It is the policy of the University of Arkansas for Med
by ellena-manuel
All individuals who are in a position to con...
Logistics Challenges
Logistics Challenges
by cheryl-pisano
The New Dimensions. ITDS: . Are the PGA Data Sets...
ACE Presentation for Industry
ACE Presentation for Industry
by danika-pritchard
Office of Enforcement and Import Operations. Food...
ACE Presentation for Industry
ACE Presentation for Industry
by natalia-silvester
Office of Enforcement and Import Operations. Food...
FDA 21 CFR Part 11 Compliance
FDA 21 CFR Part 11 Compliance
by debby-jeon
Charles Yan, PhD. Senior Director, Clinical Data ...
FDA Public Workshop – Variant Classification
FDA Public Workshop – Variant Classification
by lindy-dunigan
Session 4: Future directions for data sharing, st...
Patient Engagement in Drug Development
Patient Engagement in Drug Development
by debby-jeon
:. Experiences, Good Practices and Lessons Learne...
the FC the control
the FC the control
by payton
PMA P080002: FDA Summary of Safety and Effectivene...
Building Our Information
Building Our Information
by madison
+ Data. Future. The NLM Update – Part 2. Betsy ...
Future Directions in Symptom-Driven Consumer Applications
Future Directions in Symptom-Driven Consumer Applications
by danika-pritchard
Ed Daniels. mHealth Networking . Conference. Maki...
Summary of FDA and NIST efforts toward metrics and standard
Summary of FDA and NIST efforts toward metrics and standard
by tatiana-dople
. Content by . Marc . Salit. & Justin . Zoo...
Investigator Responsibilities for Research
Investigator Responsibilities for Research
by trish-goza
Shannon Simmons, BA, CIP. March 14, 2014. Process...
Trans-Atlantic regulatory
Trans-Atlantic regulatory
by tawny-fly
cooperation and harmonisation. Focus . on . IDMP:...
FDA Tree Nut Risk Assessment
FDA Tree Nut Risk Assessment
by alexa-scheidler
and Human Salmonellosis. National Pecan . Sheller...
41 st
41 st
by yoshiko-marsland
NCBFAA Annual Conference. . CAPT. Domenic J. Ve...
IT Strategic Plan Todd Simpson, Chief Information Officer, FDA
IT Strategic Plan Todd Simpson, Chief Information Officer, FDA
by pamella-moone
May 16, 2017. Welcome!. 2. nd. Annual OIMT Outre...
SHEDDING LIGHT ON AN
SHEDDING LIGHT ON AN
by olivia-moreira
SHEDDING LIGHT ON AN FDA VISIT Joyce Nancarrow Tu...
1 Pediatric Clinical Investigator Training
1 Pediatric Clinical Investigator Training
by lois-ondreau
GCP: . Tips on Clinical Trial Conduct and . Prepa...
Department of Health and Human Services2 OFFICE OF 2INSPECTOR GENERAL
Department of Health and Human Services2 OFFICE OF 2INSPECTOR GENERAL
by anastasia
Daniel R LevinsonInspector General The mission of ...
Clinical and Nonclinical Inspections
Clinical and Nonclinical Inspections
by claire
n and Research or CBER conducting clinical resear...
Al Crouse, CVRx ; Owen Faris, FDA; Ravi Nabar, Illumina;
Al Crouse, CVRx ; Owen Faris, FDA; Ravi Nabar, Illumina;
by adia
Joseph Sapiente, MDIC; Sara Sulfridge, Baxter. Apr...
Department of Health and Human Services
Department of Health and Human Services
by daisy
FDA’Daniel R. LevinsonInspector General OEI-0...
Accelerated Partnering
Accelerated Partnering
by bery
for Effective Recalls Recall Modernization: E ven ...
Writing and Holding an IND- IIT Development
Writing and Holding an IND- IIT Development
by osullivan
Week 3- Proposing and Conducting a Clinical Trial....
Drug Availability Reporting and Expectations
Drug Availability Reporting and Expectations
by bitsy
(. iDare. ). Melanie Singh. Problem. 2022 ended wi...
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
by adah
Jingjing Ye, PhD. BeiGene. PSI Journal Club: Bayes...
U.S. Regulatory implementation of estimand framework: Background and status
U.S. Regulatory implementation of estimand framework: Background and status
by elysha
John Scott, Ph.D., FDA/CBER/OBE. Joint PSI, EFSPI...
Perspectives on the Animal Rule
Perspectives on the Animal Rule
by mia
What is the Animal Rule?. The Basics. J.E. Estep, ...